Victory Capital Management Inc Precision Biosciences Inc Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	BUY	$1.15 - $3.34 $13,901 - $40,373	12,088 New	12,088 $19,000
Q3 2020 Nov 09, 2020	SELL	$4.65 - $8.73 $909,261 - $1.71 Million	-195,540 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$4.66 - $8.7 $1.82 Million - $3.4 Million	-391,179 Reduced 66.67%	195,540 $1.63 Million
Q1 2020 May 04, 2020	SELL	$5.05 - $15.01 $132,375 - $393,457	-26,213 Reduced 4.28%	586,719 $3.54 Million
Q4 2019 Feb 06, 2020	BUY	$6.32 - $19.66 $47,267 - $147,037	7,479 Added 1.24%	612,932 $8.51 Million
Q4 2019 Feb 04, 2020	BUY	$6.32 - $19.66 $2.08 Million - $6.47 Million	329,268 Added 119.22%	605,453 $4.9 Million
Q3 2019 Nov 12, 2019	BUY	$8.03 - $14.82 $1.12 Million - $2.07 Million	139,355 Added 101.85%	276,185 $2.32 Million
Q2 2019 Aug 15, 2019	BUY	$11.88 - $16.94 $1.34 Million - $1.91 Million	113,030 Added 474.92%	136,830 $1.81 Million
Q1 2019 May 03, 2019	BUY	$17.44 - $17.95 $415,072 - $427,210	23,800 New	23,800 $427,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.